

Karin E Smedby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403072/publications.pdf>

Version: 2024-02-01

178
papers

5,840
citations

81743

39
h-index

91712

69
g-index

180
all docs

180
docs citations

180
times ranked

9271
citing authors

#	ARTICLE	IF	CITATIONS
1	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
2	Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. <i>Gut</i> , 2005, 54, 54-59.	6.1	257
3	Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 329-336.	3.3	253
4	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223
5	Brain metastases admissions in Sweden between 1987 and 2006. <i>British Journal of Cancer</i> , 2009, 101, 1919-1924.	2.9	191
6	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). <i>Nature Genetics</i> , 2010, 42, 1126-1130.	9.4	177
7	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<sc>MCL</sc>): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	1.2	170
8	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	9.4	166
9	Lymphoma development in patients with autoimmune and inflammatory disorders – What are the driving forces?. <i>Seminars in Cancer Biology</i> , 2014, 24, 61-70.	4.3	150
10	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
11	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , 2016, 127, 1007-1016.	0.6	130
12	Autoimmune and inflammatory disorders and risk of malignant lymphomas – an update. <i>Journal of Internal Medicine</i> , 2008, 264, 514-527.	2.7	128
13	Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. <i>BMJ</i> , The, 2017, 358, j3951.	3.0	106
14	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
15	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
16	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. <i>PLoS Genetics</i> , 2011, 7, e1001378.	1.5	93
17	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. <i>Lancet Haematology</i> , the, 2014, 1, e74-e84.	2.2	93
18	Functional loss of μ leads to NF- κ B deregulation in aggressive chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2015, 212, 833-843.	4.2	85

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. <i>Nature Communications</i> , 2014, 5, 3856.	5.8	78
20	Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?. <i>Arthritis and Rheumatology</i> , 2017, 69, 700-708.	2.9	76
21	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
22	Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. <i>Seminars in Cancer Biology</i> , 2011, 21, 293-298.	4.3	73
23	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 52-65.	0.9	70
24	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	0.6	70
25	On the way towards a "CLL prognostic index"™: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. <i>Leukemia</i> , 2014, 28, 710-713.	3.3	69
26	Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 3700-3707.	0.4	68
27	Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014. <i>Gut</i> , 2020, 69, 453-461.	6.1	62
28	Cancer survival statistics for patients and healthcare professionals – a tutorial of real-world data analysis. <i>Journal of Internal Medicine</i> , 2021, 289, 12-28.	2.7	61
29	The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study. <i>BMC Cancer</i> , 2015, 15, 850.	1.1	60
30	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
31	Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. <i>British Journal of Dermatology</i> , 2016, 174, 95-103.	1.4	58
32	Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population. <i>Gastroenterology</i> , 2019, 156, 614-622.	0.6	55
33	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	1.6	54
34	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 1-14.	0.9	52
35	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
36	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50

#	ARTICLE	IF	CITATIONS
37	Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. <i>Journal of Clinical Oncology</i> , 2017, 35, 1522-1529.	0.8	48
38	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 1547-1554.	3.3	46
39	Association Between Long-term Oral Contraceptive Use and Risk of Crohn's Disease Complications in a Nationwide Study. <i>Gastroenterology</i> , 2016, 150, 1561-1567.e1.	0.6	43
40	Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. <i>British Journal of Surgery</i> , 2017, 104, 278-287.	0.1	43
41	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 360-369.	1.7	42
42	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
43	Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009: trends in cure proportions by clinical characteristics. <i>American Journal of Hematology</i> , 2015, 90, 1128-1134.	2.0	36
44	Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time: a population-based comparative study. <i>Journal of Cancer Survivorship</i> , 2015, 9, 599-609.	1.5	35
45	The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. <i>Journal of Internal Medicine</i> , 2017, 282, 360-370.	2.7	35
46	Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. <i>BMC Gastroenterology</i> , 2017, 17, 23.	0.8	35
47	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.4	34
48	Risk of infections in patients with myeloproliferative neoplasms: a population-based cohort study of 8363 patients. <i>Leukemia</i> , 2021, 35, 476-484.	3.3	32
49	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	2.8	32
50	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	0.9	31
51	No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. <i>Breast Cancer Research</i> , 2018, 20, 142.	2.2	30
52	Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 106-113.e2.	0.6	28
53	Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. <i>Cancer Medicine</i> , 2018, 7, 114-122.	1.3	28
54	Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 581-586.	0.5	28

#	ARTICLE	IF	CITATIONS
55	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	3.2	27
56	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	1.0	27
57	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. <i>Journal of Internal Medicine</i> , 2019, 285, 455-468.	2.7	27
58	Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 337-344.	0.8	26
59	Probability, rate and timing of reconstructive surgery following colectomy for inflammatory bowel disease in Sweden: a population-based cohort study. <i>Colorectal Disease</i> , 2015, 17, 882-890.	0.7	24
60	Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. <i>Leukemia</i> , 2015, 29, 748-751.	3.3	24
61	Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study. <i>British Journal of Haematology</i> , 2020, 189, 1083-1092.	1.2	24
62	Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 1020-1028.	2.0	23
63	Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma – A population-based study from Sweden. <i>European Journal of Haematology</i> , 2018, 101, 106-114.	1.1	23
64	Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. <i>American Journal of Hematology</i> , 2020, 95, 652-661.	2.0	23
65	An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. <i>European Journal of Haematology</i> , 2018, 100, 88-97.	1.1	22
66	Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study. <i>BMC Medicine</i> , 2020, 18, 238.	2.3	22
67	Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2. <i>Epigenetics</i> , 2016, 11, 449-455.	1.3	21
68	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018, 131, 2541-2551.	0.6	21
69	Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs – a Swedish cohort study of risks by time, drug and lymphoma subtype. <i>Rheumatology</i> , 2021, 60, 809-819.	0.9	21
70	Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 887-896.	1.1	20
71	Risk of Ischemic Stroke and Major Bleeding in Patients with Atrial Fibrillation and Cancer. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104560.	0.7	20
72	High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. <i>British Journal of Haematology</i> , 2019, 184, 192-201.	1.2	19

#	ARTICLE	IF	CITATIONS
73	ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. <i>Biomedicines</i> , 2020, 8, 170.	1.4	19
74	Risk of disability pension in patients following rectal cancer treatment and surgery. <i>British Journal of Surgery</i> , 2015, 102, 1426-1432.	0.1	18
75	Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patientsâ€”A nationwide study. <i>International Journal of Cancer</i> , 2020, 146, 682-691.	2.3	18
76	Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 597-605.	0.6	18
77	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. <i>BMC Medical Genetics</i> , 2014, 15, 113.	2.1	17
78	Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment. <i>Acta OncolÃ³gica</i> , 2015, 54, 1770-1780.	0.8	17
79	Surgical Treatment in Childhood-onset Inflammatory Bowel Diseaseâ€”A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 157-166.	0.6	17
80	Vitamin D Receptor Genotypes, Ultraviolet Radiation Exposure, and Risk of Non-Hodgkin Lymphoma. <i>American Journal of Epidemiology</i> , 2011, 173, 48-54.	1.6	16
81	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. <i>Haematologica</i> , 2016, 101, e369-e373.	1.7	16
82	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. <i>Haematologica</i> , 2018, 103, e158-e161.	1.7	16
83	Population-based study of patients with primary SjÃ¶rgrenâ€™s syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 225-232.	0.6	16
84	Outcomes of relapsed/refractory diffuse large Bâ€”cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second lineâ€”A populationâ€”based study of 736 patients. <i>British Journal of Haematology</i> , 2022, 198, 267-277.	1.2	16
85	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
86	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15
87	Comparison of the NCCNâ€”IPI, the IPI and PIT scores as prognostic tools in peripheral Tâ€”cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
88	Evaluation of the antibody response to the EBV proteome in EBVâ€”associated classical Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2020, 147, 608-618.	2.3	15
89	Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. <i>Leukemia Research</i> , 2014, 38, 682-690.	0.4	14
90	Chemotherapeutic intensity and survival differences in young patients with diffuse large Bâ€”cell lymphoma: a Swedish Lymphoma Registry study. <i>British Journal of Haematology</i> , 2016, 175, 614-622.	1.2	14

#	ARTICLE	IF	CITATIONS
91	Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2016, 13, 413-424.	0.3	14
92	Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 207-212.	0.6	14
93	Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 789-800.	1.9	14
94	Family history of colorectal cancer and survival: a Swedish population-based study. <i>Journal of Internal Medicine</i> , 2020, 287, 723-733.	2.7	14
95	Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy. <i>American Journal of Hematology</i> , 2017, 92, 251-258.	2.0	13
96	Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators. <i>Journal of Clinical Oncology</i> , 2018, 36, 2718-2725.	0.8	13
97	Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 3116-3131.	0.6	13
98	Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study. <i>British Journal of Haematology</i> , 2020, 189, 106-116.	1.2	13
99	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	1.1	13
100	Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1671-1681.	2.5	13
101	Work Loss Duration and Predictors Following Rectal Cancer Treatment among Patients with and without Prediagnostic Work Loss. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 987-994.	1.1	12
102	Hodgkin lymphoma in children, adolescents and young adults – a comparative study of clinical presentation and treatment outcome. <i>Acta Oncologica</i> , 2018, 57, 276-282.	0.8	12
103	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	1.2	12
104	Checkpoint <i>CD47</i> expression in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, 580-589.	1.2	12
105	Application of precision medicine in clinical routine in haematology – Challenges and opportunities. <i>Journal of Internal Medicine</i> , 2022, 292, 243-261.	2.7	12
106	Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	11
107	Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1663-1673.	0.9	11
108	Sarcoma of the breast: breast cancer history as etiologic and prognostic factor – A population-based case-control study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 669-675.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study. <i>Cells</i> , 2021, 10, 394.	1.8	11
110	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	2.2	11
111	Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. <i>American Journal of Epidemiology</i> , 2017, 185, 681-687.	1.6	10
112	Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. <i>Radiotherapy and Oncology</i> , 2018, 126, 424-430.	0.3	10
113	Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. <i>Annals of Oncology</i> , 2018, 29, 1882-1883.	0.6	10
114	Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 740-748.	2.0	10
115	Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study. <i>Journal of Internal Medicine</i> , 2021, 290, 1048-1060.	2.7	10
116	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3463-3472.	0.8	10
117	Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 694-696.	3.3	9
118	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 105-115.	1.3	9
119	Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study. <i>Blood Cancer Journal</i> , 2021, 11, 100.	2.8	9
120	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017. <i>Haematologica</i> , 2022, 107, 740-743.	1.7	9
121	Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. <i>European Journal of Cancer</i> , 2015, 51, 751-757.	1.3	8
122	Lost workdays in uterine cervical cancer survivors compared to the general population: impact of treatment and relapse. <i>Journal of Cancer Survivorship</i> , 2016, 10, 514-523.	1.5	8
123	Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma. <i>International Journal of Cancer</i> , 2017, 141, 1345-1354.	2.3	8
124	Increasing incidence of colorectal cancer among the younger population in Sweden. <i>BJS Open</i> , 2020, 4, 645-658.	0.7	8
125	Fertility-related information received by young women and men with cancer – a population-based survey. <i>Acta Oncologica</i> , 2021, 60, 976-983.	0.8	8
126	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. <i>Blood Advances</i> , 2021, 5, 1638-1647.	2.5	8

#	ARTICLE	IF	CITATIONS
127	Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 583-589.	0.6	7
128	Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 119-126.	1.1	7
129	Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. <i>Journal of Rheumatology</i> , 2015, 42, 690-694.	1.0	6
130	A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. <i>Human Molecular Genetics</i> , 2018, 27, 1809-1818.	1.4	6
131	Real-world evidence in safety assessment of new treatments. <i>Lancet Haematology</i> , 2018, 5, e510-e511.	2.2	6
132	Relative and absolute cancer risks among Nordic kidney transplant recipients—a population-based study. <i>Transplant International</i> , 2020, 33, 1700-1710.	0.8	6
133	Psychiatric Disorders Are Associated with Increased Risk of Sepsis Following a Cancer Diagnosis. <i>Cancer Research</i> , 2020, 80, 3436-3442.	0.4	6
134	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
135	Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2021, 192, 551-559.	1.2	6
136	Cancer survivorship and work loss—what are the risks and determinants?. <i>Acta Oncologica</i> , 2014, 53, 721-723.	0.8	5
137	Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 307-308.	0.5	5
138	Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study. <i>British Journal of Haematology</i> , 2021, 192, 75-81.	1.2	5
139	Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. <i>British Journal of Haematology</i> , 2022, 196, 437-440.	1.2	5
140	Use of Antibiotics and Risk of Psychiatric Disorders in Newly Diagnosed Cancer Patients: A Population-Based Cohort Study in Sweden. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	5
141	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. <i>European Journal of Haematology</i> , 2022, 108, 369-378.	1.1	5
142	Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study. <i>British Journal of Cancer</i> , 2020, 122, 1242-1249.	2.9	4
143	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021, 50, 1325-1334.	0.9	4
144	Statin use and survival in 16,098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. <i>British Journal of Haematology</i> , 2021, 195, 552-560.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Cancer in young adulthood – classifying the intensity of treatment. <i>Acta Oncologica</i> , 2022, 61, 809-813.	0.8	4
146	Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors – A population-based cohort study from Sweden and Denmark. <i>Cancer Medicine</i> , 2019, 8, 4918-4927.	1.3	3
147	Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients. <i>International Journal of Cancer</i> , 2019, 145, 1200-1208.	2.3	3
148	<p>Cardiovascular Diseases And Psychiatric Disorders During The Diagnostic Workup Of Suspected Hematological Malignancy</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1025-1034.	1.5	3
149	Immune checkpoint inhibitors in cancer treatment and potential effect modification by age. <i>Acta Oncologica</i> , 2020, 59, 247-248.	0.8	3
150	Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden. <i>British Journal of Haematology</i> , 2021, 194, 568-579.	1.2	3
151	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 270-275.	0.6	2
152	Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State. <i>Acta Oncologica</i> , 2020, 59, 949-958.	0.8	2
153	Concordance in survival among first-degree relatives diagnosed with indolent lymphoid malignancies including chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2020, 105, 779-785.	1.1	1
154	Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden. <i>Blood</i> , 2018, 132, 2975-2975.	0.6	1
155	Detailed anatomic site and melanoma prognosis: A population-based study of 6288 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9563-9563.	0.8	1
156	Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony. <i>Blood</i> , 2021, 138, 2617-2617.	0.6	1
157	Overall survival and registration of cutaneous T-cell lymphoma patients in Sweden: a multi-center cohort and validation study. <i>Acta Oncologica</i> , 2022, 61, 597-601.	0.8	1
158	Adjuvant Hormone Therapy – Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-7.	2.3	1
159	Introduction to the symposium – Targeted therapy in B-cell malignancies –™. <i>Journal of Internal Medicine</i> , 2017, 282, 358-359.	2.7	0
160	A multivariable approach for risk markers from pooled molecular data with only partial overlap. <i>BMC Medical Genetics</i> , 2019, 20, 128.	2.1	0
161	Author's reply to: A note on competing risks in analyses of cancer-specific mortality. <i>International Journal of Cancer</i> , 2019, 145, 1706-1707.	2.3	0
162	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0

#	ARTICLE	IF	CITATIONS
163	Late toxicities in non-Hodgkin lymphoma: extended follow-up matters. <i>Lancet Haematology</i> , 2021, 8, e242-e243.	2.2	0
164	Sentinel node location and patient survival in trunk and extremity melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20006-e20006.	0.8	0
165	Regular Aspirin Use and Risk of Non-Hodgkin Lymphoma: A Prospective Analysis in the Nurses' Health Study. <i>Blood</i> , 2014, 124, 2990-2990.	0.6	0
166	Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF- κ B Deregulation in Aggressive Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 297-297.	0.6	0
167	Clinical Impact of Stereotyped Antigen Receptors in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3280-3280.	0.6	0
168	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	0.6	0
169	ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome. <i>Blood</i> , 2015, 126, 1712-1712.	0.6	0
170	EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player. <i>Blood</i> , 2015, 126, 4126-4126.	0.6	0
171	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. <i>Blood</i> , 2015, 126, 5263-5263.	0.6	0
172	Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors. <i>Blood</i> , 2016, 128, 3199-3199.	0.6	0
173	Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study. <i>Blood</i> , 2018, 132, 571-571.	0.6	0
174	Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden. <i>Blood</i> , 2019, 134, 399-399.	0.6	0
175	Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study. <i>Blood</i> , 2021, 138, 2534-2534.	0.6	0
176	Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
177	Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL C <i>omplete</i> Project. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
178	NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden. <i>BMC Cancer</i> , 2022, 22, 75.	1.1	0